Schedule 13D ownership disclosure
AXOVANT SCIENCES LTD
Security class unavailable · CUSIP: G0750W104
Event date: 2017-07-01
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 75,000,000
- Percent of class
- 69.8000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000903423-17-000448
- Form type
- SC 13D
- Filer
- Sio Gene Therapies Inc.
- CIK
- CIK 1636050
- Filed
- Jul 06, 2017
- Reporting period
- Jul 01, 2017
- Description
- Schedule 13D beneficial ownership